Comparison The Therapeutic Effect Of Curcumin Nanomicelle And Metformin In Women With Polycystic Ovarian Syndrome

Phase 2

• Conditions: Polycystic Ovary Syndrome.; Polycystic Ovarian Syndrome; E28.2

• Registration Number: IRCT20090422001836N11
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

Ages 18 to 40
Observe 12 Follicles Or More In Size Of 2-9 Mm In The Ovary By Ultrasound
Oligomenorrhea or Amenorrhea In The Last 6 Months
Testosterone Levels Above 0.7 ng/dl
Serum Insulin Levels Above 16 U/ml

Exclusion Criteria

Pregnancy And Lactation During The Last 90 Days And Discontinuation Of Medication During Treatment
Liver And Kidney Failure During The Last 90 Days And Discontinuation Of Medication During Treatment
Thyroid Dysfunction During The Last 90 Days And Discontinuation Of Medication During Treatment
Hyper Prolactinemia During The last 90 Days And Discontinuation Of Medication During Treatment
Adrenal Dysfunction During The Last 90 Days And Discontinuation Of Medication During Treatment
Congenital Adrenal Hyper Plasia During The Last 90 Days And Discontinuation Of Medication During Treatment
Cushing's Syndrome During The Last 90 Days And Discontinuation Of Medication During Treatment
Use Of Contraceptives During The Last 90 Days And Discontinuation Of Medication During Treatment
Taking Estrogen And Progesterone In The Last 90 Days And Discontinuing Medication During Treatment
Ovulation Induce Medication For The Last 90 Days And Discontinue Medication During Treatment
Use Of Anti-Androgen Drugs During The Last 90 Days And Discontinuation Of Medication During Treatment
Insulin Use During The Last 90 Days And Discontinuation Of Medication During Treatment

Study & Design

• Study Type: interventional
• Study Design: Not specified